{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-008486","form_type":"8-K","ticker":"DSGN","cik":"0001807120","company_name":"Design Therapeutics, Inc.","filed_at":"2022-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.401561+00:00","generated_at":"2026-06-25T22:35:43.087249+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Design Therapeutics Q1 net loss $13.3M; cash $371.2M; DT-216 Phase 1 underway","bullets":["Net loss of $13.3M for Q1 2022; R&D expenses $8.8M, G&A $4.6M.","Cash, cash equivalents and marketable securities of $371.2M as of March 31, 2022.","DT-216 Phase 1 single-ascending dose trial in Friedreich ataxia patients; topline data expected H2 2022.","DT-216 received FDA Fast Track designation for FA.","Preclinical data for Fuchs endothelial corneal dystrophy GeneTAC molecules showed up to 99% reduction in toxic RNA foci."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-008486","json":"https://secwatch.observer/filing/0000950170-22-008486.json","markdown":"https://secwatch.observer/filing/0000950170-22-008486.md","text":"https://secwatch.observer/filing/0000950170-22-008486.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1807120/000095017022008486/0000950170-22-008486-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1807120/000095017022008486/dsgn-20220509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T22:35:43.087249+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}